A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)



Status:Recruiting
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/27/2019
Start Date:May 30, 2018
End Date:June 2022
Contact:Idera Study Monitor
Email:patientinfo@iderapharma.com
Phone:877-888-6550

Use our guide to learn which trials are right for you!

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma

A Phase 3 global, multi-center, open-label comparison of ipilimumab with and without
intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease
progression while on nivolumab or pembrolizumab

Inclusion Criteria:

1. Subjects must be willing and able to sign the informed consent and comply with the
study protocol.

2. Subjects must be ≥18 years of age.

3. Subjects must have histologically confirmed metastatic melanoma with measurable (by
RECIST v1.1), stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC
disease that is accessible for injection.

4. Patients must have confirmed progression during or after treatment with either
nivolumab or pembrolizumab. Confirmed progression is defined as:

- Radiological progression (confirmed at least 4 weeks after the initial scan
showing PD); or

- (For progression based solely on worsening of non-target or new, non-measurable
disease) confirmation by an additional scan at least 4 weeks after the initial
scan unless it is accompanied by correlative symptoms.

In addition, all the following must hold:

1. No intervening anti-cancer therapy between the last course of nivolumab or
pembrolizumab and the first dose of study treatment is allowed except for local
measures (e.g., surgical excision or biopsy, focal radiation therapy).

2. The interval between last nivolumab or pembrolizumab and start of study treatment
should be at least 21 days with no residual anti-PD-1-related immune toxicities
in excess of Grade 1 severity.

3. If BRAF mutation status is unknown, before randomization the subject must have
BRAF testing performed using an approved assay method.

4. Patients with BRAF-positive tumor(s) are eligible for the study if they received
prior treatment with a BRAF inhibitor (alone of in combination with a MEK
inhibitor) or declined targeted therapy.

5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.

6. Patients must meet the following laboratory criteria:

1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500/mm3)

2. Platelet count ≥ 75 x 10^9/L (75,000/mm3)

3. Hemoglobin ≥ 8.0 g/dL (4.96 mmol/L)

4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine
clearance ≥ 60 mL/minute

5. Aspartate aminotransferase (AST) ≤ 2.5 x ULN; alanine aminotransferase (ALT) ≤
2.5 x ULN; AST/ALT < 5 x ULN if liver involvement

6. Serum bilirubin ≤ 1.5 x ULN, except in subjects with Gilbert's Syndrome who must
have a total bilirubin < 3 mg/dL

7. Women of childbearing potential (WOCBP) and men must agree to use effective
contraceptive methods from Screening throughout the study treatment period and until
at least 90 days after the last dose of either ipilimumab or IMO-2125, whichever is
later.

8. WOCBP must have a negative pregnancy test (serum or urine).

Exclusion Criteria:

1. Ocular melanoma.

2. Prior therapy with a toll-like receptor (TLR) agonist, excluding topical agents.

3. Prior ipilimumab treatment with the exception of adjuvant treatment completed ≥6
months prior to enrollment

4. Systemic treatment with interferon (IFN)-α within the previous 6 months.

5. Known hypersensitivity to any oligodeoxynucleotide.

6. Active autoimmune disease requiring disease-modifying therapy at the time of
Screening.

7. Subjects requiring systemic steroid therapy should be receiving ≤ 10 mg/day of
prednisone (or equivalent) for the 2 weeks preceding start of study.

8. Subjects with another primary malignancy that has not been in remission for at least 3
years, with the exception of non-melanoma skin cancer, curatively treated localized
prostate cancer with non-detectable prostate-specific antigen, cervical carcinoma in
situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and
thyroid cancer (except anaplastic).

9. Active systemic infections requiring antibiotics

10. Active hepatitis A, B, or C infection.

11. Known diagnosis of human immunodeficiency virus (HIV) infection.

12. Women who are pregnant or breastfeeding.

13. Prior severe reaction to treatment with a human antibody that cannot be managed with
standard supportive measures.

14. Known central nervous system, meningeal, or epidural disease. However, subjects with
known brain metastases are allowed if the brain metastases are stable for ≥4 weeks
before the first dose of study treatment.

15. Impaired cardiac function or clinically significant cardiac disease.
We found this trial at
26
sites
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Phone: 404-778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Principal Investigator: Amy Weise, MD
Phone: 313-576-9764
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Los Angeles, California 90033
213) 740-2311
Principal Investigator: Gino In, MD
Phone: 323-865-3071
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Baltimore, Maryland 21204
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Timothy Kuzel, MD
Phone: 312-942-5526
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2139 Auburn Ave
Cincinnati, Ohio 45219
(513) 585-2000
The Christ Hospital For more than 120 years, The Christ Hospital has been a leader...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45267
Principal Investigator: Rekha Chaudhary, MD
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Brian Gastman, MD
Phone: 216-636-9521
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Easton, Pennsylvania 18045
Principal Investigator: Sangiv Agarwala, MD
Phone: 484-503-4152
?
mi
from
Easton, PA
Click here to add this to my saved trials
Falls Church, Virginia 22042
Principal Investigator: Sekwon Jang
Phone: 703-970-6430
?
mi
from
Falls Church, VA
Click here to add this to my saved trials
Gilbert, Arizona 85234
Principal Investigator: Fade Mahmoud
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Greenslopes, Queensland 4120
?
mi
from
Greenslopes,
Click here to add this to my saved trials
Indianapolis, Indiana 46256
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40207
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami Beach, Florida 33140
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
1 Medical Center Drive
Morgantown, West Virginia 26506
Principal Investigator: Joanna Kolodney, MD
Phone: 304-293-7374
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Sajeve Thomas, MD
Phone: 321-841-7303
?
mi
from
Orlando, FL
Click here to add this to my saved trials
223 N Van Dien Ave
Ridgewood, New Jersey 07450
(201) 447-8000
The Valley Hospital The Valley Hospital is a fully accredited, acute care, not-for-profit hospital serving...
?
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Sacramento, California 95816
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
3855 Health Sciences Drive
San Diego, California 92093
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Scottsdale, Arizona 85338
Principal Investigator: Alan Tan, MD
Phone: 623-207-3000
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Seattle, Washington 98101
(888) 862-2737
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials